PET scan to tell treatment effects from tumor growth in glioblastoma
Part of Cancer clinical trials.
This study uses a special PET scan to help doctors tell the difference between side effects of radiation (pseudoprogression) and actual tumor growth in people with glioblastoma. It aims to avoid unnecessary treatments and guide the next steps in your care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have glioblastoma that is IDH-wildtype, WHO grade 4
- You are 18 years or older
- Your MRI shows new or increased enhancement in the radiation area at least 3 months after finishing chemoradiation
- Your doctor is uncertain whether the MRI changes are due to treatment effects or tumor recurrence
- You have not had any treatment for recurrence yet
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether special MRI scans and blood tests can help tell the difference between true tumor growth (progression) and a treatment-related reaction called 'pseudoprogression' in people with glioblastoma. The goal is to make treatment decisions more accurate.
This study uses a special PET/CT scan to take detailed pictures of your brain tumor. It may help doctors better understand your glioma and plan your treatment.
This study uses special PET scans (fluciclovine and FDG) and advanced MRI to create a detailed metabolic profile of glioblastoma. It may help doctors better understand your tumor before surgery.
This trial tests whether a special PET scan can tell the difference between actual tumor growth and treatment-related changes in people with aggressive brain cancer (high-grade glioma). If you have had radiation and an MRI shows a growing lesion, this study may help clarify the cause.
This early-phase study uses special PET/MRI scans to look at how a newly diagnosed high-grade glioma is changing under standard treatment. The goal is to see whether these scans can better assess the disease, which may help guide future care.
This study tests a special imaging agent called fluoroethyltyrosine (FET) to see if it can better detect brain tumors on PET scans. It may help doctors decide if a tumor has come back after treatment or better guide initial biopsy or surgery.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.